Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Saturday morning. The brokerage issued a sell rating on the stock.

Several other brokerages also recently commented on CANF. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, November 12th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st.

Can-Fite BioPharma Stock Performance

Shares of CANF opened at $1.55 on Friday. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69. The stock’s 50-day simple moving average is $1.73 and its 200 day simple moving average is $2.27. The stock has a market capitalization of $5.49 million, a price-to-earnings ratio of -0.87 and a beta of 1.36.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC increased its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. 21.00% of the stock is owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.